(Q41904258)

13 October 2017

0 references

Discrepant MR and [(18)F]Fluoroethyl-L-Tyrosine PET Imaging Findings in a Patient with Bevacizumab Failure (English)

1 reference

13 October 2017

1 reference

4

1 reference

13 October 2017

Norbert Galldiks

1

1 reference

13 October 2017

Christian P Filss

series ordinal

2

1 reference

13 October 2017

Roland Goldbrunner

series ordinal

3

1 reference

13 October 2017

8 September 2012

1 reference

13 October 2017

5

1 reference

based on heuristic

inferred from page(s)

published in

Case reports in oncology

1 reference

13 October 2017

5

1 reference

13 October 2017

3

1 reference

13 October 2017

490-494

1 reference

Patterns of progression in malignant glioma following anti-VEGF therapy: perceptions and evidence

13 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3529567

Emerging clinical principles on the use of bevacizumab for the treatment of malignant gliomas

5 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3529567

Imaging of non- or very subtle contrast-enhancing malignant gliomas with [¹¹C]-methionine positron emission tomography

5 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3529567

O-(2-18F-fluoroethyl)-L-tyrosine PET predicts failure of antiangiogenic treatment in patients with recurrent high-grade glioma.

18 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3529567

Antiangiogenic therapy for patients with glioblastoma: current challenges in imaging and future directions.

18 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3529567

Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group

18 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3529567

Bevacizumab plus irinotecan in recurrent glioblastoma multiforme

18 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3529567

O-(2-[18F]fluoroethyl)-L-tyrosine PET combined with MRI improves the diagnostic assessment of cerebral gliomas

18 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3529567

One week on/one week off: a novel active regimen of temozolomide for recurrent glioblastoma

18 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3529567

18 August 2018

Identifiers

DOI

10.1159/000342480

1 reference

13 October 2017

1 reference

13 October 2017

PubMed publication ID

23271997

1 reference